News Release

International science team solve biological mystery

Debate over whether a single hydrogen atom exists is finally settled

Peer-Reviewed Publication

University of Leicester

FRM Core

image: This is the core of the Munich reactor FRM II in use, showing the blue Cherenkov radiation. view more 

Credit: Copyright: J. Neuhaus / FRM II, TUM

This news release is available in German.

An international team of researchers, led by the University of Leicester, has solved a long-standing mystery in biology, by identifying the molecular structure of a vital biological chemical. The debate – which has raged within the scientific community for years – boils down to something as simple as a hydrogen atom: is it there, or is it not?

The controversy centres around a form of enzyme called a heme (or haem, as in haemoglobin) at the centre of which is an iron atom (Fe) called a 'ferryl' which becomes oxidised when a reacting heme is in an intermediate state called Compound I. The question that has taxed biological chemists for decades is whether this oxidation involves just an oxygen atom (O), or a hydroxyl group (OH). The difference being one hydrogen ion, or in other words, a proton.

Much has been written in the scientific literature about this ferryl heme, some scientists arguing that it carries a proton, while others have been equally adamant that no proton is present. Resolving this fundamental inconsistency has implications for understanding of oxidative processes within living cells, which is crucially important for drug development.

Professors Peter Moody and Emma Raven from the University of Leicester, working with neutron crystallography experts from the Institut Laue-Langevin in Grenoble, the Maier-Leibnitz Zentrum (MLZ) near Munich, and the University of Manchester have now solved the mystery of the ferryl heme Compound I structure using a method that has not previously been applied to this problem: neutron crystallography.

"Finding out where all the hydrogens are is key to understanding the way enzymes work," said Professor Moody. "The ability to capture intermediates at cryogenic temperatures combined with the information available from neutron crystallography, means that we can finally see them."

Structures of proteins are commonly determined using X-ray crystallography, in which X-rays are fired at a crystalline form of the protein and the resulting diffraction pattern can be used to calculate the molecular structure. While this process works fine in general, it cannot be used to identify the location of hydrogen atoms for various reasons. Neutron protein crystallography, a technique originally developed in the 1960s, uses neutrons instead of X-rays – which eliminates these problems and enables the detection of individual hydrogen atoms. The team used neutron cryo-crystallography, which has the additional complication of using very low temperatures to cryo-trap the enzyme intermediate.

And the answer turns out to be… the ferryl heme in Compound I is NOT protonated. But, unexpectedly, the results showed that one of the amino acid side chains (a histidine) on the molecule IS doubly protonated, which raises questions of its own in terms of mechanisms for oxygen activation in heme enzymes.

"The exact structure of ferryl heme has been a long and difficult problem for the heme community to resolve," said Professor Raven. "Through our collaborators in Grenoble and Munich, we have been lucky to have had access to excellent neutron beamlines in Europe, which has meant that we were in an excellent position to try new and different approaches that worked very nicely. The single crystal EPR experiments at Manchester were essential to help us verify the stability of the ferryl species."

The paper 'Neutron cryo-crystallography captures the protonation state of ferryl heme in a peroxidase' has now been published in Science.

###

  • Neutron crystallography resolves long-standing molecular mystery
  • Research has implications for understanding of oxidative processes within living cells which is crucially important for drug development
  • Leicester team worked with colleagues in France, Germany and Manchester

The research was supported by The Leverhulme Trust, BBSRC, The Wellcome Trust, Bruker UK Ltd, EU FP7, Institut Laue-Langevin and Heinz Maier-Leibnitz Zentrum.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.